EcoDrugPlus

Matrix Metallopeptidase 2

Ensembl ID : ENSSFOG00015009635
Gene Symbol: MMP2
1 Cross references
207 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSSFOG00015022660
Gene Symbol: MMP9
3 Cross references
215 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSSFOG00015006500
Gene Symbol: LOC114911942
3 Cross references
197 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSSFOG00015027794
Gene Symbol: MTOR
1 Cross references
76 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSSFOG00015012472
Gene Symbol: LOC108931071
3 Cross references
76 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSSFOG00015020179
Gene Symbol: MC1R
1 Cross references
157 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSSFOG00015007906
Gene Symbol: MC1R
1 Cross references
158 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSSFOG00015021308
Gene Symbol: MC3R
3 Cross references
138 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSSFOG00015009899
Gene Symbol: MC4R
1 Cross references
107 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSSFOG00015032727
Gene Symbol: MTNR1A
3 Cross references
188 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSSFOG00015019644
Gene Symbol: MME
3 Cross references
234 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSSFOG00015000605
Gene Symbol: LOC108936375
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).